Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2)

Autor: Lebwohl, Mark G., Leonardi, Craig L., Mehta, Nehal N., Gottlieb, Alice B., Mendelsohn, Alan M., Parno, Jeff, Rozzo, Stephen J., Menter, M. Alan

Publikováno v: In Journal of the American Academy of Dermatology February 2021 84(2):398-407

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

51523 The Phase 3 Vehicle-Controlled ASCEND Trial of Polyethylene Glycol Based Topical Isotretinoin (TMB-001 0.05% ointment) for Treatment of X-Linked and Autosomal Recessive Congenital Ichthyosis: Pharmacokinetic Results Compared with 80 mg Oral Isotretinoin

Autor: Bunick, Christopher, Huynh, Thy N., MS, Jackson, Lee, Lara Wine, Kempers, Steven E., Mendelsohn, Alan M., Eursken, Brenda, Ahson, Anum, Raiz, Jessica, Teng, Joyce MC.

Publikováno v: In Journal of the American Academy of Dermatology September 2024 91(3) Supplement:AB332-AB332

Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5-year data from reSURFACE 1 and reSURFACE 2

Autor: Fernandez, A. P., Dauden, E., Gerdes, S., Lebwohl, M. G., Menter, M. A., Leonardi, C. L., Gooderham, M., Gebauer, K., Tada, Y., Lacour, J. P., Bianchi, L., Egeberg, A., Pau-Charles, I., Mendelsohn, A. M., Rozzo, S. J., Mehta, N. N.

Publikováno v: Fernandez, A P, Dauden, E, Gerdes, S, Lebwohl, M G, Menter, M A, Leonardi, C L, Gooderham, M, Gebauer, K, Tada, Y, Lacour, J P, Bianchi, L, Egeberg, A, Pau-Charles, I, Mendelsohn, A M, Rozzo, S J & Mehta, N N 2022, ' Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome : post hoc analysis of 5-year data from reSURFACE 1 and reSURFACE 2 ', Journal of the European Academy of Dermatology and Venereology, vol. 36, no. 10, pp. 1774-1783 . https://doi.org/10.1111/jdv.18167

Background: Limited data are available on long-term efficacy and safety of biologics in patients with psoriasis and metabolic syndrome (MetS), a common comorbidity. Objectives: This analysis updates tildrakizumab efficacy and safety for up to 5 years

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::1bdc916438aced2f09ca0b3e06780342
https://pubmed.ncbi.nlm.nih.gov/35460287